Skip to main content

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

  • ${value}

Filter Results (2329${count})

  • Research Grant, 2024
    Developing an Open-access Repository of High-quality Digital Measurement Tools for Use in Parkinson’s Disease Research and Care

    Study Rationale: This study will bring together leaders in Parkinson’s disease (PD) and digital health innovation and measurement to develop and maintain an open-access repository of high-quality...

  • 2022: Accelerated Therapeutics Program, 2024
    (SUPPLEMENT) Small Molecule Mitochondrial Modulators for the Treatment of Parkinson's Disease

    Study Rationale: Mitochondrial dysfunction is a crucial driver of the initiation and progression of Parkinson’s disease (PD). Mitochondria are structures that produce cellular energy, and in neurons...

  • Parkinson’s Disease Therapeutics Pipeline Program, 2024
    Assessment of IRL757 for the Treatment of Apathy in Parkinson's Disease

    Study Rationale: People with Parkinson’s disease (PD) frequently develop a loss of motivation and initiative. Such apathy can be burdensome for patients and their families and caregivers and is...

  • Alpha-Synuclein Post-Translational Modifications Quantification Program, 2024
    Development of anAssay for Quantification of Alpha-synuclein and its Modifications

    Study Rationale: Many studies have shown that a protein called alpha-synuclein is abnormal in Parkinson's disease (PD), forming toxic aggregates that move through the brain and cause neuronal cell...

  • Research Grant, 2024
    Discovery of PET Tracers for Measuring Alpha-synuclein

    Study Rationale: The discovery of new treatments for Parkinson’s disease (PD) has been slowed by the amount of time (years) it takes to determine whether a drug was effective in a clinical trial. New...

  • 2022: Accelerated Therapeutics Program, 2024
    (SUPPLEMENT) Innovative Therapies for Parkinson’s Disease Through a Novel, Unexploited Gene Expression Mechanism Rooted in Human Genetics Enabling a Precision-medicine Approach

    Study Rationale: Parkinson’s disease (PD) and Alzheimer’s disease (AD) are neurodegenerative disorders caused by an accumulation of protein aggregates that leads to cell death. Genetic studies suggest...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.